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Abstract
Background:  In spite of the recognized diagnostic potential of biomarkers, the quest for
squelching noise and wringing in information from a given set of biomarkers continues. Here, we
suggest a statistical algorithm that – assuming each molecular biomarker to be a diagnostic test –
enriches the diagnostic performance of an optimized set of independent biomarkers employing
established statistical techniques. We validated the proposed algorithm using several simulation
datasets in addition to four publicly available real datasets that compared i) subjects having cancer
with those without; ii) subjects with two different cancers; iii) subjects with two different types of
one cancer; and iv) subjects with same cancer resulting in differential time to metastasis.
Results: Our algorithm comprises of three steps: estimating the area under the receiver operating
characteristic curve for each biomarker, identifying a subset of biomarkers using linear regression
and combining the chosen biomarkers using linear discriminant function analysis. Combining these
established statistical methods that are available in most statistical packages, we observed that the
diagnostic accuracy of our approach was 100%, 99.94%, 96.67% and 93.92% for the real datasets
used in the study. These estimates were comparable to or better than the ones previously reported
using alternative methods. In a synthetic dataset, we also observed that all the biomarkers chosen
by our algorithm were indeed truly differentially expressed.
Conclusion:  The proposed algorithm can be used for accurate diagnosis in the setting of
dichotomous classification of disease states.
Background
In spite of a plethora of available choices [1-4] to statisti-
cally analyze the high-dimension data derived from gene
microarrays or serum proteomic profiles, a single method
of choice remains elusive. Two main objectives motivate
such analyses: first, to identify novel biomarkers that char-
acterize specific disease states so as to gain biological and
therapeutic insights and second, to identify patterns of
expression that will discriminate among disease states and
aid in diagnostic classification. Clearly, the statistical
Published: 10 October 2006
BMC Bioinformatics 2006, 7:442 doi:10.1186/1471-2105-7-442
Received: 13 May 2006
Accepted: 10 October 2006
This article is available from: http://www.biomedcentral.com/1471-2105/7/442
© 2006 Mamtani et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Bioinformatics 2006, 7:442 http://www.biomedcentral.com/1471-2105/7/442
Page 2 of 12
(page number not for citation purposes)
methods suited to achieve one objective may differ from
the methods appropriate for the other purpose – not only
in terms of the procedural assumptions and details but
also in terms of the results. Several extensive reviews deal
with this issue [1,5-10].
For the purpose of diagnostic classification using biomar-
ker data, a common statistical option is to use linear dis-
criminant functions [11,12]. However, this choice is not
straightforward because of an important asymmetric dis-
position of the typical datasets. For example, the number
of biomarkers (usually several thousands) greatly exceeds
the number of samples (usually in hundreds or less). Each
biomarker, therefore, must be assessed for its potential
association with the disease status leading to a problem of
multiple comparisons [13]. Consequently, while on the
one hand a few highly significant associations may mask
other important associations; on the other hand noisy,
false positive associations can be detected. A successful
use of linear discriminant analyses therefore rests on a
proper choice of a finite but informative subset of the
biomarkers.
A natural approach to supervised diagnostic classification
using such datasets would be to assume expression of each
biomarker as a diagnostic test [14,15]. Since the expres-
sion levels of many of the biomarkers can be expected to
be correlated with each other [15], the problem in diag-
nostic classification is that of finding an optimum combi-
nation of the correlated diagnostic tests that will
maximize the discriminatory performance. The formal
optimization methods available for this problem are how-
ever constrained to a limited number of diagnostic
tests[16] An analysis of a dataset of n biomarkers will need
to consider a total of 2n-1 combinations of the biomark-
ers, which can demand immense computation time in the
context of the microarray experiments. We believe, how-
ever, that a simpler solution to this problem exists, which
can be arrived at by using classical statistical techniques.
Here, we suggest a statistical algorithm to circumvent
these problems of data dimension and asymmetry and
using four datasets of differing nature demonstrate the use
of the proposed technique for the purpose of dichoto-
mous diagnostic classification.
Results
Proposed statistical algorithm
Contingent upon the assumption that each biomarker can
be considered as a diagnostic test, we propose a three-step
procedure (Fig. 1) to arrive at an optimum combination
of the biomarkers that will have a high degree of diagnos-
tic accuracy. The proposed algorithm consists of three
steps: screening the biomarkers individually based on the
Performance Index (Pi) which is a function of the esti-
mated area under the receiver characteristic curve (AUC),
using stepwise multiple regression analysis to select the
top ranked n-1 biomarkers, and then combining the
selected biomarkers using a linear discriminant function.
A detailed description of the algorithm and its implemen-
tation in Stata 7.0 statistical package (Stata Corp, College
Station, Texas) is provided in the Methods section and in
Section 1 of the Additional File (see additional file 1). To
assess the validity of our proposed algorithm, we used five
datasets with 2 diagnostic classes each – four real datasets
[17-20] (abbreviated as OvCa, LuMe, LLML and BrCa and
described in Table 1) and a synthetically generated dataset
(abbreviated as Syn1) comprising 50 samples of each
diagnostic class and 1000 genes (described in the Meth-
ods section below).
Results from step 1 of the proposed algorithm
In the context of microarray experiments, the Zipf's law
suggests that there will be only few genes with very highly
differential expression levels [21-24]. Analogous to this
interpretation of the Zipf's law, in our situation, we
expected a small subset of biomarkers to be very highly
discriminatory for diagnostic classification. Fig 2 shows
that this indeed was the case. The proportion of biomark-
ers with performance index exceeding 0.4 (which corre-
sponds to an AUC more than 0.9 or less than 0.1) was
0.31%, 2.36%, 1.25%, 0.03% and 11.1% in the OvCa,
LuMe, LLML, BrCa and Syn1 datasets, respectively. This
observation indicated that a combination of only few
biomarkers is likely to be diagnostically sufficient.
Further, the OvCa dataset (as available from the source)
was already normalized while the other three datasets
used raw expression level values. As can be expected from
the non-parametric nature of the area under the ROC
curve statistic, this preprocessing (or the lack of it) of the
data did not alter the diagnostic performance across the
datasets. To explore this formally, we generated a syn-
thetic dataset (Syn2) with 100 biomarkers and 100 sub-
jects using raw as well as normalized expression values.
The area under the ROC curve for the biomarkers –
whether raw or normalized – was comparable (see Section
2 of additional file 1).
Results from step 2 of the proposed algorithm
As there were 132, 32, 38 and 43 subjects (Table 1) in the
training subsets of the OvCa, LuMe, LLML and BrCa data-
sets, respectively; we chose 131, 31, 37 and 42 biomarkers
in the corresponding full models in these datasets. We
observed that the number of biomarkers that were
retained in the final model in stepwise multiple linear
regression analyses was strikingly low. For example, in the
OvCa dataset 18 (of 131), in the LuMe dataset 5 (of 31),
in the LLML dataset 3 (of 37) and in the BrCa dataset 5 (of
42) biomarkers were retained in the final model. In spite
of these small number of biomarkers, the regressionBMC Bioinformatics 2006, 7:442 http://www.biomedcentral.com/1471-2105/7/442
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model fit was excellent within each dataset (see Section 3
in additional file 1).
In the OvCa dataset, the mass-by-charge (M/Z) values
identifying the 18 biomarkers retained in the final model
were as follows: 2.8549, 25.4956, 25.6844, 25.7791,
28.7005, 42.4388, 220.7513, 243.4940, 245.2447,
434.6859, 463.1559, 463.5577, 463.9596, 464.3617,
619.0509, 8033.385, 8035.058, and 8038.405. In the
LuMe dataset the following five probe sets were retained
in the final model: junction plakoglobin, tumor-associ-
ated calcium signal transducer 2, adaptor-related protein
complex 2, EGF-containing fibulin-like extracellular
matrix protein 1 and polymerase I and transcript release
factor. In the LLML dataset the three genes that were
retained in the final model were LYN V-yes-1 Yamaguchi
sarcoma viral related oncogene homolog, Calpain 2 and
the Epb72 gene. In the BrCa dataset, the five genes that
were retained in the final model were: NGFIA-binding
protein-2 (NAB2), aurora kinase A interacting protein 1
(AURKAIP1), V-set domain containing T cell activation
inhibitor 1 (VTCN1), zinc finger protein 473(ZNF473)
and leucine-rich repeats and calponin homology (CH)
domain containing 3 (LRCH3). The ROC curve for the
Table 1: The publicly available datasets used in the current study
Characteristic Dataset #1 Dataset #2 Dataset #3 Dataset #4
Authors Petricoin et al, 2002 [19] Gordon et al, 2002 [18] Golub et al, 1999 [17] van't Veer et al 2002 [20]
Dataset alias OvCa LuMe LLML BrCa
Biomarker Proteomic mass spectra Gene expression Gene expression Gene expression
# Biomarkers 15,154 12,533 7,129 24,481
Diagnostic 
classes
Ovarian cancer Normal Lung adeno-carcinoma Mesothelioma Acute lymphocytic 
leukemia
Acute myeloid 
leukemia
Metastasis 
within 5 years
Metastasis after 
5 years
N (Total) 162 91 150 31 46 26 34 44
N (Training) 83 49 16 16 27 11 17 26
N (Test set) 79 42 134 15 19 15 17 18
The statistical algorithm used in the present study Figure 1
The statistical algorithm used in the present study. Numbers correspond to the steps described in the text. Steps 1–3 
were used on a training subset. The training subset was randomly chosen for the OvCa dataset while for the other two data-
sets, the training sets used by primary authors were used. Validation was done separately in the training and test subset within 
each dataset.BMC Bioinformatics 2006, 7:442 http://www.biomedcentral.com/1471-2105/7/442
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diagnostic performance of each biomarker retained in the
final model within each dataset is shown in Fig A1 (see
additional file 1).
Results from step 3 of the proposed algorithm
Table 2 summarizes the results of the linear discriminant
analyses. The discriminant scores for each dataset were
obtained from the respective training subsets. It was
observed that the discriminant score was clearly differen-
tially clustered in the two diagnostic classes in each data-
set (Fig. 3A to 3D) and that there was an extremely low or
absent misclassification in the training set. The discrimi-
nant model fits as indicated by the model R2, Mahalano-
bis D2, χ2, canonical correlation coefficient, eigenvalues
and Wilk's λ (Table 2) demonstrated that the model was
highly suited for all the datasets used in this study. Within
the training sets the discriminant rule correctly classified
100% of the subjects in the training subsets of all the data-
sets.
Validation of the proposed algorithm
Next, we validated the diagnostic performance of the diag-
nostic rule in the three steps. First, an examination of the
distribution of the discriminant score (insets to Fig 3E to
3H) revealed a markedly bimodal disposition in all the
datasets suggesting the likelihood of an efficacious classi-
fication.
Second, we generated receiver operating characteristic
(ROC) curves using the discriminant score as a predictor
of the diagnostic class in the training subset as well as the
test subset within each dataset. We observed that the Wil-
coxon estimates AUC were high and comparably similar
across the training- and test- sets within each of the three
datasets (Fig 3E to 3H). Therefore, we estimated the over-
all prediction accuracy of the discriminant score for each
dataset by combining the training- and test-subsets (Fig
3E to 3H).
The AUC for the discriminant score in the training and test
sets combined were 100% (95% confidence interval not
estimable) for the OvCa dataset, 99.9% (95% confidence
interval 99.7%–100%) for the LuMe dataset, 96.7% (95%
confidence interval 91.3% – 100%) for the LLML dataset
and 94.3% (95 confidence interval 89.3% – 99.5%) for
the BrCa dataset. The use of the AUC is only appropriate
for this study because the high values of AUC indicate very
high partial AUCs related to small false positives, which
are required for a study of early detection of cancer. We
have further addressed the issue of using AUC in the Dis-
cussion section. From these ROC curves we also observed
that the cut-off points that maximized the discriminatory
performance were -1.09 for the OvCa dataset, 0.43 for the
LuMe dataset, -0.26 for the LLML dataset and 0.22 for the
BrCa dataset corroborating the general assumption that
positive and negative discriminant scores will indicate the
two diagnostic classes. At these best cut-off points, we esti-
mated the sensitivity and specificity of the discriminant
score, the estimates for sensitivity and specificity were
100% and 100% for the OvCa dataset, 100% and 97% for
the LuMe dataset, 98% and 92% for the LLML dataset, and
91% and 91% for the BrCa dataset, respectively.
Third, we scrutinized the list of biomarkers retained in the
final model of the synthetically designed dataset (Syn1) of
gene expression profile of 1000 hypothetical genes across
2 diagnostic classes in 100 subjects. In truth, the synthetic
dataset contained 240 genes that were differentially
expressed across the diagnostic classes. For details of the
correlation among genes see Section 4 of the additional
file 1. We observed that all the 22 genes retained in the
final model (see Section 2e in the additional file 1) were
included in the list of the known list of differentially
expressed genes in this dataset thereby indicating that the
algorithm did not falsely discover a differential expression
of any gene in this dataset.
Comparison of the proposed algorithm with other 
methods
Our algorithm needs a single pass through the dataset for
estimating the area under ROC curve for each biomarker
and is, therefore, computationally less intense than other
data mining techniques used in similar situations e.g.
principal components analyses [25,26], singular value
decomposition (SVD) [27,28], genetic algorithms (GA)
[19], k-nearest neighborhood (kNN) [29,30], support vec-
The performance index (Pi) derived from the area under the  ROC curve of the biomarkers within each dataset Figure 2
The performance index (Pi) derived from the area 
under the ROC curve of the biomarkers within each 
dataset. The curves demonstrate that the diagnostic per-
formance of the biomakers follows the Zipf's law. The colors 
for the four datasets are used consistently in Figure 3 and 
Supplementary Figures 1 and 2 (see additional file 1).BMC Bioinformatics 2006, 7:442 http://www.biomedcentral.com/1471-2105/7/442
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tor machines (SVM) [31-34], logical analysis of data
(LAD) [35], classical and fuzzy neural networks (NN) [36-
39], self-organizing maps (SOM) [40] and statgram (SG)
[41]. A comparison of the results of these techniques with
the results from our analyses in the real datasets used in
this study (Table 3) demonstrates that the diagnostic accu-
racy of the proposed algorithm is comparable to or higher
than that of the presently available analytical options.
Also, in the Syn1 dataset we compared the classification
performance of several currently used methods of classifi-
cation with that of our proposed algorithm (Table 4) and
observed a clear advantage of our algorithm – a parsimo-
nious choice of the number of biomarkers without loss of
diagnostic performance.
Discussion
Our proposed statistical algorithm highly accurately clas-
sified subjects in all the datasets used in this study. The
algorithm is simple, uses statistical techniques that are
established in biostatistical literature and can be imple-
mented by most statistical software packages. The choice
between parametric versus non-parametric methods for
analysis of microarray data has been a matter of intense
debate [42]. It is possible that the high diagnostic accuracy
achieved by our algorithm may be due to a combination
of non-parametric and parametric methods. The sug-
gested approach can be discounted on the basis of the fact
that it differs from a more conventional approach of using
Student's t test only with regards to the use of area under
the ROC curve. It is recognized that the area under the
ROC curve follows a Mann-Whitney distribution [43].
Therefore, the first step in the suggested approach can be
viewed narrowly as just a non-parametric alternative to
the conventional approach.
However, in addition to its advantages mentioned earlier,
the proposed algorithm offers one more subtle improve-
ment. Since the true association of a biomarker with the
disease remains unknown, various methods exist that
indirectly estimate the local false discovery rate (FDR)
which gives the probability that a biomarker identified to
be associated with disease is in fact falsely identified [44].
Our suggested approach can directly estimate the local
FDR (which in the lexicon of diagnostic test performance
evaluation can be equated to the inverse of the positive
predictive value) of a biomarker by varying the cut-off
value for expression level over the observed range of val-
ues. This approach also does not presuppose a predefined
single estimate of the local FDR. Indeed, the FDR can be
allowed to vary based on the definition of expression level
used for diagnostic classification. In spite of all these
advantages, however, several caveats need to be men-
tioned before generalizing the results of the present study.
Study limitation 1: the choice of AUC for ranking 
biomarkers
The first step of our proposed algorithm makes use of
ROC curves and therefore places some restrictions on the
generalization of the approach to various situations. The
real datasets that we used for validation in our study had
diverse aims. For instance, the OvCa dataset was primarily
designed for early detection of cancer, the LuMe and LLML
datasets have therapeutic implications while the BrCa
dataset has a prognostic significance. In the case of early
detection of cancer, the emphasis is really on reducing the
false positivity rate and, therefore, the area under the
entire ROC curve may not be as useful [45]. However, in
the analyses conducted in the present study our focus was
on discriminating between two classes and all the datasets
were used as examples of two class biomarker datasets.
Fortuitously, in the OvCa dataset we found a perfect dis-
crimination including the leftward of the ROC curve
where the specificity was high.
Study limitation 2: the proposed algorithm is suitable for 
two classes only
First, our analysis demonstrates the use of the algorithm
only in the situation of dichotomous classification. Theo-
retically, the technique can be extended to diagnostic out-
comes with multiple classes. For example, ROC curves can
be drawn for multiple category outcomes and the multi-
class counterpart of the discriminant function analysis is
available [46-51]. In that case, in the first step of our algo-
rithm one would need to estimate the volume under the
multidimensional ROC surface as a non-parametric meas-
ure of the diagnostic performance of each biomarker. A
Table 2: Summary of the discriminant model performance in the training subsets of the datasets used in the present study
Statistic Dataset
OvCa (n = 132) LuMe (n = 32) LLML (n = 38) BrCa (n = 43)
Model R2 0.9680 0.9618 0.9170 0.7436
Wilk's λ 0.0320 0.0382 0.0830 0.2564
Mahanalobis D2 127.69 94.38 50.91 11.57
χ2 416.54 89.77 85.88 52.40
Canonical correlation 0.9839 0.9807 0.9576 0.8623
Eigenvalue 30.26 25.17 11.05 2.90BMC Bioinformatics 2006, 7:442 http://www.biomedcentral.com/1471-2105/7/442
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The diagnostic performance of the proposed statistical algorithm Figure 3
The diagnostic performance of the proposed statistical algorithm. (A-D) The probability of the predicted diagnostic 
class in the training set of each dataset studied. Gradient background indicates a continually increasing or decreasing likelihood 
of the diagnostic classes. The abscissa indicates the discriminant score generated using the proposed algorithm. (E-H) Evalua-
tion of the diagnostic performance of the proposed algorithm. The plots are ROC curves for the entire dataset (that is training 
and test sets combined) since the diagnostic performance of the discriminant score was consistently high in the training and 
test subsets when assessed separately. Area under the ROC curve (AUC) was non-parametrically estimated using the Wil-
coxon method. Insets show the strikingly bimodal distribution of the discriminant scores in the entire (that is training and test 
subsets combined) datasets. SE, standard error.BMC Bioinformatics 2006, 7:442 http://www.biomedcentral.com/1471-2105/7/442
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potential difficulty can arise in the coding scheme to be
used for the outcome variable for multiple linear regres-
sion analysis to be conducted in the second step of the
algorithm. The coding scheme needs to be compatible
with the assumption of linearity implicit in the regression
analysis. As this compatibility is unlikely to be known a
priori, we suggest that the numerical codes for the diagnos-
tic classes be permuted and the regression be used for each
permutation. One can, then, choose the regression that
gives the best fit. Finally, one can use the multiclass discri-
minant function analysis on the chosen subset of biomar-
kers. In the present study, we did not conduct these
analyses because Stata modules for estimating volume
under surface and for multi-class discriminant analyses
are not currently available.
Study limitation 3: the proposed algorithm can not identify 
all the differentially expressed biomarkers
The algorithm is designed to make use of the diagnostic
performance of a biomarker battery – it is not designed to
identify all the biomarkers that are differentially expressed
across the diagnostic classes. Consequently, exclusion of a
biomarker from those retained in the analysis will not
equate to a non-association of that biomarker with the
disease state or process. For example, in the Syn1 dataset
the algorithm chose only 22 of the actually 240 differen-
tially expressed gene. Also, of the 18 biomarkers in the
OvCa dataset that Zhu et al [41] had previously identified,
only two were included in our list of 18 independent
biomarkers. It has already been pointed out by Baggerly et
al [52] and Sorace and Zhan [53] that the reproducibility
of different methods in terms of the identified set of
biomarkers using the same biomarker dataset is low. Ran-
sohoff argues [54,55] that chance and bias are two major
threats to the validity of inferences in studies attempting
to associate molecular markers to disease status. For
instance, the set of biomarkers identified to be significant
may simply be a result of the way the training set was sam-
pled from the full dataset. Indeed, Michiels et al [56,57]
have demonstrated that the results obtained in the micro-
array experiments can be extremely sensitive to the sample
size and procedure of selection of the training set. Nota-
bly, the training set used by Zhu et al [41] was not the
same as the one we used in our analysis.
Study limitation 4: the choice of retention criterion for 
stepwise regression
The number of biomarkers finally retained in the stepwise
regression analyses, will depend on the criterion used for
retention (see Fig A2 in the additional file 1). In stepwise
Table 4: Comparison of the results of the proposed algorithm with other approaches using a simulated dataset (Syn1) of 100 samples 
and 1000 genes
Method Software Reference # biomarkers used Accuracy (%)
KMC Cleaver 1.0 [67] 1000 89
kNN GeneCluster 2.0 [68] 127 95
WV GeneCluster 2.0 [68] 127 97
SAM SAM for Excel [69] 203 100
PAM PAM for Excel [69] 224 100
SVM GEPAS [70] 250 100
Proposed Stata 7.0 [71] 22 100
Table 3: Comparison of the results of the proposed algorithm with other approaches reported previously using the same datasets
Dataset Method Reference Accuracy
OvCa Principal components Lilien et al, 2003 [25] 100
Wilcoxon test Sorace et al, 2003 [53] 100
Logical analysis of data Alexe et al, 2004 [35] 100
Statgram Zhu et al, 2003 [41] 100
Genetic algorithm Petricoin et al, 2002 [19] 98
Proposed algorithm Present study 100
LuMe Gene expression ratios Gordon et al, 2002 [18] 99
Proposed algorithm Present study 100
LLML Self-organizing maps Toronen et al, 1999 [40] 90
Neural networks Bicciato et al, 2003 [38] 97
ICED Bijlani et al, 2003 [65] 98
Support vector machines Furey et al, 2000 [66] 88 – 94
Proposed algorithm Present study 97
BrCa Correlation van't Veer et al [20] 83
Proposed algorithm Present study 94BMC Bioinformatics 2006, 7:442 http://www.biomedcentral.com/1471-2105/7/442
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regression models, it is customary to use a probability cri-
terion of 0.2. If this criterion is used in the biomarker
analysis, it is evident that more number of biomarkers will
be retained in the final model at the cost of an increased
complexity of the subsequent discriminant rule. Moreo-
ver, considering the high level of accuracy that we
obtained even with a very few biomarkers using a reten-
tion criterion 20 times as stringent, shows that there is
indeed a very small scope for improving the diagnostic
performance by relaxing the retention criterion. Again,
because the purpose of the analysis was to optimize the
diagnostic performance of a subset of biomarkers, to
maintain the parsimony of the final regression model, we
used a retention criterion of 0.01.
Study limitation 5: potential bias implicit within the 
proposed algorithm
We also considered if the algorithm itself is biased in favor
of detecting non-existing i.e. false associations of biomar-
kers with disease states. For this purpose, we generated
additional 1000 synthetic datasets (Syn3 – Syn1002) with
100 subjects and 100 biomarkers. Within each of these
datasets, each biomarker expression followed a standard
normal distribution N(0,1) and was thus non-differen-
tially distributed across diagnostic classes. We then con-
ducted the analyses using the proposed algorithm in each
of the 1000 datasets and observed that in 92.8% of these
samples the algorithm did not (as expected) find an asso-
ciation between any biomarker and the disease state. In
the remaining 72 samples, the algorithm found associa-
tion of one (67 samples) or two (5 samples) biomarkers
with the disease. However, the R2 values indicating the fit
of the discriminant function model ranged from 0.0192 –
0.1574 (see Fig A3 in the additional file 1) suggesting that
the model fits in these situations of non-existing associa-
tions were poor. If one compares these R2 values with
those reported in Table 2, it is clear that the algorithm did
not detect false associations.
Issues regarding inferences about validity
To this end, we conducted a further series of analyses to
ensure that the diagnostic accuracy of the proposed algo-
rithm was not merely a result of chance or bias. (i) In the
OvCa dataset, we generated 100 random training sets of
varying sizes and within each of these training sets we esti-
mated the AUC for each of the 15,154 markers (for
details, see Fig A4 in the additional file 1). We then
assessed the consistency of the AUC estimates in two
ways: first, we conducted a factor analysis on the AUC esti-
mates across all samples to assess whether the different
training sets map onto a single domain versus multiple
domains. We observed that training sets of sizes exceeding
100 were characteristically very similar to each other and
consistently identified the same biomarkers. Second, we
estimated the Spearman correlation coefficients between
each of the random training sets and the training set that
we used for the OvCa dataset. Predictably, we again
observed that training sets exceeding sizes of 100 were
very highly correlated with the training set that we used in
this study. Since our training subset comprised of 132
subjects in the OvCa dataset, we believe that our results
are unlikely to have been influenced by chance. (ii) We
obtained bootstrap estimates of the AUC for all the
biomarkers selected in the final model in 500 replicate
samples (See Fig A4 in the additional file 1) for all the
datasets. We observed that the estimate of AUC that we
obtained in the chosen training set was always very close
to the mean AUC obtained from 500 replicates even after
correcting for sampling bias (see Fig A4C in the additional
file 1). Thus, we believe that our results are robust and
faithfully reflect true associations between biomarkers
and disease status. (iii) Another important threat to valid-
ity that we considered was bias. Ransohoff [54] and Bag-
gerly et al [52] also state that if bias in selecting the
subjects in the main dataset is hard-wired into the study
then demonstration of reproducibility will not be able to
address this issue. Therefore, we conducted all our analy-
ses across four different datasets of totally different char-
acteristics. The fact that the proposed algorithm
performed very well in all the datasets pointed towards
the possibility that it is relatively insensitive to the ele-
ment of bias specific to each of the chosen datasets. How-
ever, it is also possible that all the chosen datasets had
negligible bias and therefore our results showed a consist-
ently high performance of the proposed algorithm.
Conclusion
Within the constraints imposed by the caveats mentioned
earlier, our analytical approach demonstrates a technique
to translate molecular biomarker data into clinically
meaningful and diagnostically useful information. Con-
ceptually and in a broader context, the actual use of the
biomarker batteries for detection of the disease status will
depend on a conflation of three requisites – existence and
severity of the disease under investigation; presence of
sensitive and specific biomarkers and the choice of proper
statistical analytical methods to ferret out the true rela-
tionships between disease and biomarkers. Using real and
simulated datasets, in the present study we addressed the
last two aspects only. In spite of the high discriminatory
performance of the proposed statistical algorithm in the
analytical situations considered, caution will be required
before recommending molecular biomarkers as diagnos-
tic tests against cancer as the existence and severity of can-
cer can substantially limit the generalizability of the
results. Nevertheless, early and reliable diagnosis is the
cornerstone of management of chronic diseases. In that
vein and towards that goal, the proposed approach pro-
vides a simple, novel and accurate step.BMC Bioinformatics 2006, 7:442 http://www.biomedcentral.com/1471-2105/7/442
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Methods
The algorithm
Contingent upon the assumption that each biomarker can
be considered as a diagnostic test, we designed a three-
step procedure (Fig. 1) to arrive at an optimum combina-
tion of the biomarkers that will have a high degree of diag-
nostic accuracy. A theoretical basis for this improved
diagnostic accuracy is that our proposed algorithm identi-
fies a set of independent biomarkers that predict the dis-
ease class, and since each member of this set is ensured to
be a good predictor of the disease status, a combination of
these independent biomarkers will lead to an improved
diagnostic accuracy. Following account describe the three
steps in our proposed algorithm.
Step 1: quantification of diagnostic performance of biomarkers
In the first step, we estimate the diagnostic accuracy of
each biomarker by plotting a ROC curve and estimating
the area (A) under the ROC curve. The area under an ROC
curve captures the overall diagnostic accuracy of the test.
In our proposed algorithm, a non-parametric estimate of
the area using trapezoidal rule is obtained in this step.
Since, the area under an ROC curve is constrained within
the interval (0, 1) and since an area of 0.5 represents max-
imum diagnostic uncertainty [58], we define a diagnostic
performance index of the ith biomarker as Pi = |Ai-0.5|
where Ai is the estimated area under the ROC curve based
on the expression pattern of the ith biomarker. This trans-
formation of the area under ROC curve permits consider-
ation of a bi-directional association of the biomarkers
with the disease states such that either over- or under-
expression of a particular biomarker can characterize the
disease. Thus, the biomarkers can be ranked from highest
to lowest values of Pi (for which the theoretical bounds are
0 and 0.5) with high values indicating diagnostically
informative biomarkers and low values suggesting a low
discriminatory performance of the biomarkers. However,
since the diagnostic performance of one biomarker may
be correlated with that of others, choosing the biomarkers
with highest Pi values may not ensure independent and
additive contribution of the biomarkers.
Step 2: optimizing the number of biomarkers
Therefore, the second step needs to be undertaken to opti-
mize the set of biomarkers with high and independent
diagnostic information content in a multivariate setting.
Three critical issues need to be considered in this step:
choosing an appropriate statistical method for multivari-
ate analysis, choosing the number of diagnostically
informative biomarkers to be entered into the multivari-
ate model and using an appropriate method to optimize
the number of finally selected biomarkers. With regard to
choosing the statistical method, several choices present
themselves. An obvious choice is to use the available
methods to combine multiple diagnostic tests [16]. How-
ever, because one would have only achieved, in step 1, a
ranked list of biomarkers; there remains the circular prob-
lem of trying to predefine the number of biomarkers to be
combined. Another option is to use multivariate regres-
sion analyses. As the outcome variable is – by definition –
dichotomous, the likely choices can be methods like logis-
tic regression or probit regression. However, since the pre-
dictor biomarkers will be selected on the basis of high
diagnostic performance (Pi) it is extremely likely that
these will be highly discriminant across the outcome
states. Consequently, the regression coefficients in a logis-
tic regression model may not be estimable (because of, for
instance, an infinite odds ratio) and these highly inform-
ative biomarkers are likely to be automatically dropped
from the model by statistical software packages. There-
fore, we suggest the use of multivariate linear regression
with the outcome variable being the codes for the dichot-
omous disease states (0/1).
The second issue relates to the number of biomarkers to
be included in the multivariate linear regression model.
This is not difficult in the context of a multivariate regres-
sion model because for a regression model to be identifi-
able the number of covariates must be less than the
number of observations. Thus, the number of most discri-
minant biomarkers that can be included in this model
must be less than the number of subjects included in the
analysis. Finally, the third critical issue relates to the
method of optimizing the number of biomarkers
included in the multivariate analysis. We suggest the
approach of a stepwise regression using backward elimi-
nation procedure. Considering the fact that the purpose of
this step is to optimize the cardinality of the subset of
diagnostically useful biomarkers, we suggest the use of a
strict retention criterion, that is, the maximum signifi-
cance value needed to retain a biomarker in the multivar-
iate model. It is evident that the more rigid this criterion,
the lesser the number of biomarkers that will be selected
in the final model. In our analyses we used a retention cri-
terion of 0.01.
Step 3: generating a diagnostic classification based on the optimized 
subset of biomarkers
Linear discriminant function model is an extension of the
linear regression model but can also be used in place of
logistic regression [59,60]. Therefore, we suggest the use
of a linear discriminant score using the optimized subset
of biomarkers identified in the previous step. The discri-
minant model fit can be assessed by model R2 and its com-
plement – Wilk's λ (which varies between 0 and 1 with a
smaller value indicating a better fit). If the model fit is
good, then for a given subject a discriminant score can be
generated using the unstandardized discriminant regres-
sion coefficients and the expression levels of chosen
biomarkers. The discriminant function analysis reportsBMC Bioinformatics 2006, 7:442 http://www.biomedcentral.com/1471-2105/7/442
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the centroids of the discriminant scores for subjects
belonging to different diseases states. These can be used to
predict the disease status in a given subject. Generally,
positive and negative values of the diagnostic score will
indicate two different disease states depending on the dis-
criminatory performance of the score. Thus, while use of
discriminant function analysis itself is not new to the field
of microarray data analysis [61-63], we here propose a
novel way to choose a diagnostically discriminant subset
of biomarkers by using the results of a stepwise regression
analysis procedure.
Validation of the proposed algorithm
To validate the proposed analytical approach, we used
four publicly available datasets (Table 1). Before applying
the algorithm to derive a discriminatory rule, we split each
original dataset into a training set (to derive the rule) and
a validation set (to test whether the rule discriminates
between the same diagnostic classes in an independent
group of subjects). This split was done once, before any
analysis, and the resulting validation set was used only
once for the primary analysis. We conducted the valida-
tion of this rule in three steps. First, we applied the discri-
minant rule to the independent test subset. Additionally,
we also reported the validation performance of the discri-
minant score in the training as well as entire dataset. The
diagnostic performance of the discriminant score was
assessed by estimating sensitivity, specificity and diagnos-
tic accuracy by plotting the ROC curves. Second, we com-
pared the results of our proposed approach to those
reported for other available methods of classification
using the same four real datasets that we included in the
present study. Third, we created a synthetically designed
dataset with known set of differentially expressed genes
and assessed whether the biomarkers retained in the final
model of the proposed algorithm are a subset of the
known differentially expressed genes in the synthetic data-
set. Also, in this synthetic dataset, we compared the diag-
nostic performance of the proposed algorithm with that
of other methods used for this purpose.
Datasets
For validation of the proposed algorithm, we used four
real datasets and a synthetically designed dataset. The four
real datasets (Table 1) were: serum proteomic profile of
ovarian cancer subjects and controls (referred here as
OvCa data) [19], gene expression data of subjects with
adenocarcinoma of lung compared to subjects with mes-
othelioma (LuMe dataset) [18] and gene expression pat-
tern of subjects with acute lymphocytic leukemia
compared with that of subjects with acute myeloid leuke-
mia (LLML dataset) [17] and breast cancer subjects fol-
lowed prospectively for development of metastasis within
or after 5 years of follow-up (BrCa dataset) [20]. The syn-
thetically designed dataset (Syn1) was generated using the
SIMAGE software package [64]. This dataset contained
expression values for 1000 genes for two diagnostic
classes with 50 subjects each. The detailed specifications
and input parameters used to generate this dataset are pro-
vided in Section 4 in the additional file (see additional file
1). Apart from these five datasets we used a synthetic data-
set (Syn2) to examine the influence of data preprocessing
on the estimates of AUC (see Section 2 of the additional
file 1) and 1000 datasets (Syn3 – Syn1002, see Fig A3 in
the additional file 1) to assess the likelihood of false dis-
covery in the use of the proposed algorithm. All the statis-
tical analyses were conducted using Stata 7.0 (College
Station, Texas) software package.
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